URGENT:COVID prophylaxis | Vitamin D | Latest research | NIH | CDC | Worldometer
Information about Maraviroc
FDA approval information for Maraviroc
Maraviroc was approved for use in the United States in 2007 and has had limited use.
Liver safety of Maraviroc
Mechanism of action of Maraviroc
Maraviroc (mar" a vir' ok) is relatively new antiretroviral drug that targets one of the receptors for HIV that is present on the surface of lymphocytes. Maraviroc interrupts the binding of HIV to target cells by blocking the chemokine coreceptor 5 (CCR5), a necessary receptor in the uptake of HIV into cells. Maraviroc has both in vitro and in vivo activity against HIV and several randomized controlled trials have shown that it leads to significant decline in HIV RNA levels and rises in peripheral [[CD4 T cell counts]. Maraviroc was given accelerated approval for use in HIV infection in the United States in 2007 and is currently used in a relatively small proportion of antiretroviral regimens, being recommended largely for HIV-treatment experienced adult patients with CCR5-tropic strains of HIV.
Dosage and administration for Maraviroc
Maraviroc is available as 150 and 300 mg tablets under the brand name Selzentry. The recommended dose is 150 to 600 mg twice daily in combination with other classes of antiretroviral agents. Common side effects include cough, fever, rash and dizziness.
Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Nucleoside Analogues (HIV)
- Protease Inhibitors (HIV)
HCV NS5A Inhibitors
HCV NS5B (Polymerase) Inhibitors
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Drugs for Herpes Virus Infections (HSV, CMV, others)
Drugs for Influenza